The Mars Empire: How One Candy Company Came to Own Your Pet’s Exam, Bloodwork, and X-Ray

Mars, Incorporated has quietly assembled the most vertically integrated veterinary services empire in history — clinics, laboratory, and teleradiology all under one roof. None of it is disclosed to pet owners at the point of care.

Most pet owners who walk into a Banfield Pet Hospital or a VCA Animal Hospital are thinking about their animal, not corporate structure. They don’t know — and have no particular reason to know — that the clinic they’re standing in, the diagnostic laboratory processing their pet’s bloodwork, and the teleradiologist reading their pet’s X-rays all belong to the same parent company: Mars, Incorporated, a privately held conglomerate headquartered in McLean, Virginia, best known for making M&M’s and Snickers.

This article documents the full corporate architecture of what Mars has assembled in veterinary services. It examines how the empire was built, the particular role that Antech Imaging Services — Mars’s captive teleradiology company — plays within that structure, and what the company’s academic and professional sponsorship activities mean for the future of the field. It also asks what the Federal Trade Commission, which reviewed the 2017 VCA acquisition, did not address — and what it arguably should address before its oversight window closes.

This is not a story about a bad actor doing something obviously illegal. It is a story about a legal structure that raises serious questions about competition, transparency, and informed consent — questions that neither federal regulators nor professional bodies have fully confronted.

The Corporate Map

The ownership structure of Mars’s veterinary services businesses can be traced through public corporate disclosures, Mars’s own corporate website, VCA’s SEC filings prior to its acquisition, the FTC’s 2017 consent order, and Antech’s own digital properties. The chain of ownership is not in dispute.

Mars’s corporate website confirms the Banfield, VCA, and BluePearl relationships directly under its Mars Veterinary Health division.¹ Antech Diagnostics’s own “About” page confirms that AIS is a division of Antech Diagnostics and is wholly owned by Mars, Inc.² The AIS homepage — which carries a footer reading “MARS announces SYNLAB Vet acquisition” — further confirms the Mars parentage without ambiguity.³

KPMG’s veterinary industry analysis estimates that Mars owns approximately 45% of all corporate-owned veterinary clinics in the United States — roughly 3,000 locations — making it by far the dominant corporate owner in the sector.⁴

How Mars Built It: A Thirty-Year Acquisition Timeline

Mars did not become the dominant force in veterinary services overnight. The company built its empire through a deliberate, decades-long acquisition strategy that ultimately placed the clinic, the laboratory, and the teleradiology provider under the same roof.

The result of this thirty-year strategy is a vertically integrated enterprise unlike anything that has existed in veterinary medicine. A pet owner at a Banfield clinic — or increasingly at VCA — can generate revenue for Mars at every touchpoint: the office visit, the wellness plan subscription, the blood panel sent to Antech Diagnostics, and the radiograph interpreted by Antech Imaging Services.

Antech Imaging Services: The Captive Teleradiologist

Antech Imaging Services holds a distinctive position in the Mars corporate architecture. It is not merely a company that Mars happens to own; it is the designated teleradiology provider for the clinics Mars also owns. This creates a structure that exists nowhere else in veterinary medicine — and raises questions that the industry has largely declined to examine.

The AIS origin

AIS’s own “Who We Are” page, published through the Antech Imaging Academy website, states the history plainly: “Founded in 1999 as DarkHorse Medical Ventures, DarkHorse joined VCA, Inc. in 2005. DarkHorse moved to ANTECH Diagnostics in 2010 with a name change to ANTECH Imaging Services (AIS®). AIS® is a Division of ANTECH Diagnostics and is wholly owned by Mars, Inc.”¹³

That chronology matters. AIS existed before VCA acquired it, and before Mars acquired VCA. It was not purpose-built as a captive provider. It became one through acquisition. The operational consequence of that structure — that Banfield and VCA clinics send their radiology reads to a company under common ownership — is a product of the 2017 merger that the FTC reviewed and approved.

Scale and market position

AIS describes itself as providing “over 600,000 telemedicine consults each year” and storing “over 920 million images,” with over 400,000 images added daily.¹⁴ It employs more than 130 board-certified specialists according to its homepage.¹⁵ These are the statistics of a dominant market player — one that happens to be the in-house provider for the largest clinic network in the country.

The pricing question

AIS’s public-facing pages do not publish per-study pricing for standard teleradiology reads. The 2026 Antech Diagnostics pricing page notes that “Antech Imaging Services pricing remains unchanged until further notice” and directs questions to Antech representatives — suggesting pricing is managed through client contracts rather than public rate sheets.¹⁶

Independent competitive pricing in the veterinary teleradiology market for a standard radiograph interpretation currently ranges from approximately $110 to $150 per study, based on publicly available pricing from independent providers operating in the market. This range represents the price at which the service is available to any clinic that chooses a non-captive provider.

The pricing transparency concern is compounded by the structure of the underlying equipment relationship. AIS, operating through Antech’s Sound™ imaging equipment division, supplies digital radiography equipment to veterinary practices. Practices that accept subsidized or low-cost equipment from Sound/Antech frequently find their imaging workflow routed to AIS for reads — a bundled arrangement that makes switching costly even for independent clinics.¹⁷ This bundling is not unique to AIS, but it is particularly notable when the equipment provider and the read provider are both subsidiaries of the same company that also owns the largest clinic chains.

The ACVR Connection: Sponsorship, Residencies, and the Pipeline

The American College of Veterinary Radiology (ACVR) is the credentialing body for veterinary radiologists in North America. Board certification by the ACVR is the terminal professional credential in the field — the qualification that distinguishes a teleradiologist from a general practitioner reading films. The ACVR’s partners and affiliates page lists Antech Imaging Services as a Silver Sponsor of the organization.¹⁸

That sponsorship relationship is significant in its own right. But the more structurally important relationship is AIS’s engagement with the residency pipeline — the training programs that produce board-certified veterinary radiologists.

Cornell University College of Veterinary Medicine

Cornell’s veterinary imaging residency program accepts three new candidates annually. According to Cornell’s own program description page, two of those three positions are sponsored by Antech Imaging Services.¹⁹ The program description further notes that “our caseload benefits from access to an Antech Imaging Services virtual teleradiology rotation.”²⁰

Cornell’s residency is one of the most prestigious in the country. AIS-sponsored residents handle expenses, stipends, and benefits that are provided in exchange for the sponsorship commitment — the specific terms are not publicly disclosed, but the AIS contact email listed for residency applicants confirms the operational relationship is managed directly by AIS staff.²¹

The Academic Cooperative

AIS operates a formal program called the Antech Academic Cooperative, which the Antech Diagnostics website describes as a commitment to “promoting the growth of the veterinary radiology profession through the active and tangible support of academic institutions and training programs.”²² According to that page, in May 2019, AIS invited residency program directors, department heads, and deans from all accredited North American veterinary universities to an Academic Forum — a meeting that twelve leaders from nine universities attended.

AIS’s own Academy website lists radiologists who completed their Cornell residency and subsequently joined AIS, including at least one who holds a “joint position in AIS and Cornell University.”²³ This joint appointment model — in which a practicing AIS teleradiologist simultaneously holds an academic role at a university whose residency program AIS sponsors — represents a deep integration of the commercial and academic spheres.

AIS extended its educational footprint in 2025 through a partnership with VETgirl, sponsoring a full Diagnostic Imaging Certificate program available at no cost to veterinarians and technicians. The program was curated by AIS’s Chief Medical Officer and marketed through the broader “Mars family,” with an Antech blog post explicitly referring to VETgirl as “a fantastic partner within the Mars family.”²⁴ VETgirl is an independent continuing education company — but the Mars familial framing in the Antech post is notable.

The FTC’s Unfinished Business

When Mars announced its acquisition of VCA in January 2017, the Federal Trade Commission opened an antitrust review. The result was a consent order, finalized in December 2017, requiring Mars to divest 12 specialty and emergency veterinary clinics in 10 geographic markets where the combined Mars/VCA footprint would have created unacceptable concentration in the provision of specialty or emergency care.²⁵

The FTC’s analysis was competent within its defined scope. The relevant markets identified were “individual specialty and off-hours emergency veterinary services,” analyzed on a local geographic basis.²⁶ The FTC correctly identified that in several local markets, the post-merger entity would be the only provider of certain specialty services, and it required divestitures to restore competition in those localities.

What the FTC did not analyze — and what the consent order does not address — is a different set of competitive concerns that arise from the vertical integration of the clinic, laboratory, and teleradiology functions under a single owner.

What the FTC did not examine

The captive teleradiology arrangement. AIS serves as the designated teleradiology provider for Banfield and VCA clinics. Because both the clinic and the teleradiology provider are owned by Mars, the normal competitive market for radiology reads does not operate within that relationship. Independent teleradiology companies — which compete for the business of independent clinics and other hospital groups — do not compete for Banfield or VCA reads. The FTC’s horizontal analysis of clinic competition did not address this vertical arrangement and its effect on the teleradiology market.

Antech Diagnostics laboratory tying. Antech Diagnostics is the reference laboratory for Banfield and VCA clinics, again under common Mars ownership. Whether those clinics use Antech Diagnostics by policy, by economic incentive, or by the absence of a competitive internal alternative is not publicly documented. But the structural incentive for a captive arrangement is clear: revenue from the lab read stays within Mars. Independent laboratory companies — IDEXX and others — compete for the business of independent practices but not for the captive Banfield/VCA relationship.

The equipment bundling strategy. Sound™ (Powered by Antech™) is the imaging equipment division of Antech Diagnostics. Sound provides digital radiography and ultrasound equipment to veterinary practices. When an independent clinic acquires Sound equipment, it often also acquires a workflow that routes images to AIS for reads. This bundled equipment-plus-reads model is a known mechanism by which market share in teleradiology is built and defended. The FTC did not examine whether this equipment-PACS-reads bundle constitutes a tying arrangement that may warrant attention under Section 1 or Section 2 of the Sherman Act.

What the law may require

This publication is not a legal authority and does not render legal opinions. The following is a summary of questions that the vertical integration described above appears to raise under existing law, based on publicly available legal analysis of the veterinary industry.

The federal Anti-Kickback Statute (AKS) applies primarily to Medicare and Medicaid — and veterinary medicine is not a Medicare-covered service. However, numerous state veterinary practice acts contain analogous prohibitions on fee-splitting and referral payments that may apply to self-referral arrangements within a corporate structure. Whether a clinic that directs radiology reads exclusively to a corporate sibling entity — without disclosing that relationship to the pet owner or offering a competitive alternative — satisfies the elements of a prohibited self-referral under applicable state law raises questions that state veterinary boards have not publicly examined.

Section 2 of the Sherman Act prohibits monopolization and attempted monopolization. Whether AIS’s combination of market share, PACS integration, residency sponsorship, and captive clinic volume constitutes conduct that raises attempted monopolization concerns in the market for veterinary teleradiology services is a question that appears to meet at least the threshold for serious analytical consideration.

What Mars Doesn’t Tell You

There is nothing on the Banfield Pet Hospital website’s patient-facing materials that discloses the teleradiology relationship with AIS.²⁷ There is nothing in a standard Banfield or VCA exam room — nothing on the walls, the paperwork, or the patient discharge summary — that tells a pet owner that the company reading their pet’s X-rays is a corporate sibling of the clinic charging for it.

This is not a disclosure that consumers have demanded, or that regulators have required. The absence of disclosure is not, by itself, a legal violation. Human medicine established disclosure requirements for physician self-referral through the Stark Law precisely because Congress determined that informed consent in a commercial medical setting requires patients to know when their physician has a financial interest in the services being ordered. No equivalent requirement exists in veterinary medicine.

That regulatory gap leaves pet owners making cost and care decisions without material information. A pet owner who learns that the radiology read is performed by a Mars subsidiary — just like the clinic visit itself, just like the blood panel — may make different decisions about where to seek care, whether to seek a second opinion, or whether to ask about alternative providers. They currently have no mechanism to obtain that information at the point of care.

Conclusion: The Structure Is the Story

Mars, Incorporated has done nothing covert. Its acquisitions were publicly announced, FTC-reviewed, and documented in SEC filings. Its corporate structure is traceable through public sources. AIS’s own website states plainly that it is wholly owned by Mars. The ACVR’s partners page lists AIS as a Silver Sponsor. Cornell’s residency page lists AIS as the sponsor of two of its three annual positions. The information is available to anyone who looks.

What has not happened is a systematic examination of what this structure means — for pet owners, for independent providers competing in the teleradiology market, for the veterinary radiologists being trained in a pipeline substantially financed by the dominant commercial player, and for the regulatory bodies whose mandates cover competition in health services.

The FTC reviewed a horizontal merger in 2017 and found it largely acceptable with targeted divestitures. That review was appropriate for what it examined. It did not examine the vertical integration of the laboratory and teleradiology functions because those were not clinic competitors in the localities at issue. Seven years later, the vertical structure is more entrenched, the clinic footprint is larger, and the ten-year advance-notice requirement is approaching its expiration.

This publication will continue to document this structure, update it as Mars’s acquisitions proceed, and invite response from any of the entities described herein. Antech Diagnostics, AIS, Banfield Pet Hospital, VCA, BluePearl, and Mars, Incorporated are welcome to submit corrections, clarifications, or statements for publication. Contact information is available on this site.

The structure is the story. And the structure is fully documented in public records, for anyone who chooses to look.